LGBTQI

profileSlimcity070

LGBTQ

  • a year ago
  • 35
files (2)

ResponseDiscussion2..docx

2. Bipolar disorder (BD) is a chronic mental health condition that impacts adults of all genders, races, and ages. BD typically presents in late adolescence or early adulthood and is characterized by episodes of mania or hypomania and depression. There are several challenges and unique factors that must be taken into consideration when addressing bipolar within the LGBTQI+ population. The LGBTQI+ population is at higher risk for mental health disorders, to include bipolar disorders. The social isolation, stigma, and stress associated with being within this minority population may interact with genetic and biological predispositions and increase the risk for the presentation of BD. Furthermore, these negative experiences may exacerbate symptoms and influence the progression and management of BD (Gmelin et al., 2022).

Bipolar disorder places a high economic burden on the United States. It is estimated that BD results in an estimated $195 billion of lost funds due to direct and indirect costs. Direct cost includes ongoing medical treatment and indirect costs include loss of work or loss of home (Bessonova et al., 2020). The LBGTQI+ population members with mental health disorders experience greater indirect costs than the general population, as this population typically experiences challenges with academics, employment, and housing due to stigma (Chen, Wang, She, Qin, & Ming, 2022).  

Diagnosing BD requires a comprehensive assessment that includes a detailed psychiatric history, family history, mood charting, and identification of triggering factors. Psychiatric Mental Health Nurse Practitioner (PMHNP) can use several assessment tools to help screen for BD symptoms, such as the Mood Disorder Questionnaire or the Hamilton Depression Rating Scale (Culpepper, 2014). It is important for providers to be aware these questionaries may not be culturally sensitive to the LGBTQI+ populations, so interpretation should consider cultural context (Chen, Wang, She, Qin, & Ming, 2022).  

Treatment of BD within the LBGTQI+ population has greatest success when a combination of pharmacological and nonpharmacological treatment approaches is used. Pharmacological treatment may include mood stabilizers, antipsychotics, and antidepressants. Lithium is a mood stabilizer that acts on the sodium channels and second-messenger systems. Valproate is a mood stabilizer that enhances GABAergic activity. The PMHNP must consider how other medications may impact how these medications are metabolized. Similarly, atypical antipsychotics, such as Aripiprazole, Olanzapine, Quetiapine, can be used to manage manic or mixed episodes. However, the patient must be closely monitored for side effects, such as weight gain, sedation, or metabolic syndrome (Culpepper, 2014).

              Nonpharmacological interventions should start with psychoeducation to help patients better understand the disease process and recognize signs and symptoms of mood instability. Additionally, a positive community support system can help members of the LBGTQI+ population better manage the BD disease process. Community support may include support groups for LBGTQI+ members with BD, financial support network, or social support activities. This collaborative approach increases the likelihood that the LBGTQI+ patient will adhere to the treatment plan and ensures that the patient has the support they need to manage their mental health disorder (Moagi et al., 2021).